Molecular Characteristics
Complete Specifications
Structural Composition
Ipamorelin (5-amino-acid synthetic growth hormone–releasing peptide) + CJC-1295 No DAC (modified 29-amino-acid growth hormone–releasing factor analog)
Physical Properties
This blend combines Ipamorelin, a short synthetic pentapeptide containing non-natural amino acid residues, with CJC-1295 No DAC, a modified 29-amino-acid growth hormone–releasing factor analog featuring targeted amino acid substitutions for enhanced stability. Because the formulation contains two structurally distinct peptides of different molecular sizes, overall molecular formula and molecular weight are inherently variable and depend on blend ratios and hydration state. Lyophilized presentation supports storage stability, while protection from moisture, light, and repeated freeze–thaw cycles helps maintain structural integrity and analytical consistency for laboratory and research applications.
Research Applications
Growth Hormone Axis Modulation Research
Ipamorelin + CJC-1295 (No DAC) Blend is utilized as a research combination in studies examining coordinated activation of the growth hormone (GH) axis through ghrelin receptor (GHS-R1a) stimulation and growth hormone–releasing hormone (GHRH) receptor signaling. Laboratory investigations focus on its role in:
- GHS-R1a Activation Models: Investigation of ghrelin receptor binding dynamics and calcium-mediated intracellular signaling
- GHRH Receptor Signaling Studies: Evaluation of cAMP-dependent pathways associated with pituitary somatotroph activation
- Pulsatile Growth Hormone Release Research: Analysis of amplitude and frequency modulation under dual-receptor stimulation
- Short-Acting GHRH Analog Models: Examination of transient signaling characteristics associated with No DAC formulations
- Endocrine Feedback Regulation: Investigation of hypothalamic–pituitary feedback mechanisms
Experimental protocols commonly employ receptor-binding assays, pituitary cell culture systems, and endocrine monitoring models to characterize blend-mediated GH axis signaling responses.
IGF-1 and Anabolic Signaling Research
The Ipamorelin + CJC-1295 (No DAC) Blend has been examined in research contexts involving downstream insulin-like growth factor (IGF) signaling and anabolic pathway modulation. Key areas of investigation include:
- IGF-1 Expression Models: Evaluation of hepatic and peripheral IGF-related signaling following GH pathway activation
- PI3K-AKT Pathway Studies: Investigation of intracellular survival and growth-associated cascades
- mTOR Signaling Research: Analysis of protein synthesis–related pathway activation
- Muscle and Connective Tissue Models: Research into cellular growth and remodeling dynamics
- Signal Timing and Kinetics Analysis: Examination of coordinated pulse-driven pathway activation
These studies utilize IGF quantification assays, protein expression analysis, and cultured muscle cell systems to evaluate anabolic signaling outcomes.
Metabolic and Lipid Regulation Research
The blend has also been explored in research models examining metabolic regulation and substrate utilization pathways, including:
- Adipocyte Signaling Studies: Evaluation of intracellular pathways influencing lipid metabolism
- Glucose Utilization Models: Investigation of substrate usage dynamics under GH axis modulation
- Mitochondrial Activity Research: Analysis of cellular energy production pathways
- Metabolic Flexibility Studies: Examination of adaptive responses within endocrine-regulated systems
Laboratory protocols assess metabolic biomarkers, lipid transport signaling, and intracellular energy dynamics using biochemical and cellular assays.
Cellular Signaling and Endocrine Homeostasis Research
Additional research applications explore the blend’s combined influence on intracellular regulatory systems involved in endocrine balance and adaptive signaling, including:
- MAPK and ERK Pathway Studies: Investigation of downstream cascades associated with GH and GHRH receptor activation
- Gene Expression Profiling: Analysis of transcriptional responses linked to growth-related modulation
- Receptor Sensitivity Research: Examination of signaling attenuation and feedback regulation mechanisms
- Integrated Hormonal Feedback Systems: Analysis of coordinated endocrine regulatory networks maintaining GH axis stability
Research in this domain focuses on understanding how the combined peptide components influence growth hormone axis signaling, pulsatile endocrine dynamics, and downstream IGF-related pathways under controlled experimental conditions.
Laboratory Handling and Storage Protocols
Lyophilized Powder Storage
- Store at –20°C to –80°C in the original, sealed vial
- Protect from light exposure and moisture
- A desiccated storage environment is recommended
- Stability data suggests extended stability when stored at −20 °C or below.
Reconstituted Solution Storage
- Short-term storage: Up to 7 days at 4°C
- Long-term storage: Store at –20°C in aliquots
- Use single-use aliquots to preserve peptide integrity
- Minimize freeze–thaw cycles; single-use aliquots are strongly recommended
Stability Characteristics
Ipamorelin + CJC-1295 (No DAC) Blend is a synthetic multi-component peptide research formulation composed of short-acting growth hormone–related peptides. As a composite preparation, stability depends on proper cold storage of the lyophilized material, careful reconstitution, and minimized freeze–thaw exposure. When handled according to standard peptide laboratory protocols, the blend maintains structural integrity and solubility suitable for in vitro and analytical research applications.
Frequently Asked Questions
What is the Ipamorelin + CJC-1295 (No DAC) blend?
This is a research formulation combining:
-
Ipamorelin — a selective growth hormone secretagogue acting on the GHS-R1a receptor
-
CJC-1295 (No DAC) — a modified GHRH analog targeting the GHRH receptor without the extended half-life DAC modification
The blend enables investigation of dual-pathway activation in experimental models.
What does “No DAC” mean?
“No DAC” indicates that the CJC-1295 component does not include the Drug Affinity Complex modification. As a result, it demonstrates a shorter duration of activity in research models compared to CJC-1295 with DAC.
What is this blend commonly researched for?
In laboratory and preclinical research settings, the blend is studied for:
-
Growth hormone release signaling
-
GHS-R1a and GHRH receptor co-activation models
-
IGF-1 pathway research
-
Endocrine pulsatility investigations
-
Comparative multi-peptide pathway analysis
All applications are exploratory and conducted in controlled research environments.
Why combine Ipamorelin and CJC-1295 (No DAC)?
Researchers may combine these peptides to evaluate:
-
Complementary receptor activation
-
Coordinated endocrine signaling mechanisms
-
Experimental models requiring shorter activity windows
-
Comparative results versus DAC-modified variants
This approach may allow greater control over timing variables in certain research designs.
Is this a single peptide?
No. This is a multi-peptide blend, not a single amino acid sequence. Each component retains its distinct structural and receptor-binding characteristics within the formulation.
How is the blend supplied?
The blend is typically supplied as a lyophilized (freeze-dried) powder in sealed research vials to maintain stability during storage and shipment.
How should unreconstituted blend vials be stored?
Lyophilized blend vials should be stored:
-
Long-term: −20 °C to −80 °C
-
Short-term: 2–8 °C
Keep vials sealed and protected from light and moisture until use.
How should reconstituted blend solutions be handled and stored?
Once reconstituted:
-
Store at 2–8 °C for short-term laboratory use
-
For extended storage, aliquot and freeze at −20 °C or below
-
Minimize freeze–thaw cycles using single-use aliquots
-
Gently swirl to mix; avoid vigorous agitation
Does this blend require a Certificate of Analysis (COA)?
Yes. A Certificate of Analysis (COA) should be available for each batch, verifying identity and purity for both peptide components within the blend to ensure research quality and traceability.
Is the Ipamorelin + CJC-1295 (No DAC) blend FDA-approved?
No. This blend is not FDA-approved as a drug, supplement, or therapeutic product. It is sold exclusively as a research compound blend and must not be marketed or used for diagnostic, therapeutic, or consumption purposes.
This product is not for human consumption. It is sold strictly for research and educational purposes and is not intended to diagnose, treat, cure, or prevent any disease.
Any clinical data or research information referenced on this page is derived from peer-reviewed scientific literature and official publications. This information is provided for educational reference only and does not constitute medical advice or product claims.
By purchasing this product, you acknowledge that you are a qualified researcher and agree to use it in full compliance with all applicable laws and regulations.
